Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Definitions

• gonadotropins such as Example ⁇ that controls HCG, HMG, PMSG, FSH, LH and / or GnRH release of gonadotropins from the pituitary gland.
• Fertility denotes the ability to reproduce an individual and the capacity of the individual, a certain number of living offspring per reproduction period
• the invention relates to a drug for improving the ovary reactions and the egg and embryo production in domestic mammals in connection with biotechnological embryo transfer.
• the medicament of the invention is alternatively and preferably defined in the subclaims.
• the medicament of the invention is characterized by another, independent solution.
• This is characterized in that it consists of hormones which promote inhibin-neutralizing antibodies in conjunction with multiple ovulations (superovulation), preferably 25 with gonadotropins and / or with GnRH (Gonadotropin-releasing hormone, and / or with anti-estrogens in the form of synthetic active substances or antibodies, preferably glomiphene,
• the medicament of the invention is alternatively and preferably characterized in that it consists of specific, the biological activity of inhibin in the living
• the medicament of the invention is also alternatively and preferably characterized in that it consists of antibodies against naturally occurring
• the medicament of the invention is alternatively and preferably characterized in that it is used in the liquid phase, preferably by intravenous and / or by subcutaneous and / or by intramuscular application.
• the medicament of the invention is alternatively and preferably characterized by a method of using it.
• This method is characterized in that the application takes place as a multiple injection at defined 30 time intervals, preferably from 12 or 24 hours, over several successive days, preferably from 3.5 to 5 days. 1
• This method is also alternatively and preferably characterized in that the application in the middle 5 luteal phase, preferably on
• the method of the invention is further characterized in that the application is carried out in the same 10 or descending dosage, each with 2 identical, successive amounts.
• Inhibin generated from bFF This is therefore a cleavage product of 58 kDa inhibin.
• the medicament of the invention means antibodies which neutralize the biological activity of the inhibins produced in gonads in animals and thereby render them ineffective.
• Monoclonal antibodies are against bFF 32 kDa inhibin using hybridization technology in mice
• a specific antibody, type 256 H specifically recognizes the bovine 20 kDa ((X subunit) and 13 kDa ( ⁇ subunit) of bovine 32 kDa inhibin.
• the medicament of claim 2 is superior to ovarian responses in most domestic mammals.
• Chloprostenol is understood to mean the water-soluble sodium salt. Artificial insemination was performed 36, 48, 60, 72 hours after initiation of luteolysis with frozen sperm from a single bull.
• the rams were first cleaned with 2.5 mg protein each
• the booster amounts were given on the 20th and 50th day after the basic immunization with 2.0 and 1.8 rag protein, dissolved in
• Serum was obtained on the 7th and 10th. Day after the 2nd booster.
• Antiserum from the 4 rams was pooled and fractionated into equal volumes, 150 ml, and at
• Folltropin is a gonadropin preparation obtained from hyperphysic cells of slaughter pigs with a low LH content.
• n number of experimental animals
• Gl yellow body, determined by rectal palpation, as a characteristic of the number of ovulations.
• total number of all eggs obtained, unfertilized and the embryos,
• % numerical values related to "total", superovulation - promoting hormone
• REPLACEMENT LEAF Treatment with folltropin in group I, control group shows an average recovery of 7.9 embryos and eggs per single cell animal.
• the proportion of fertilized embryos is 66% (5.1) and the proportion of transferable embryos is 48% (3.8).
• the medicament of the invention with the combination of antibodies and gonadropines leads to an unexpected and considerable increase in the recovery of egg cells and embryos to 9.6 and the proportion of fertilized embryos to 90% (8.6) and the transferable embryos to 86 % (8.3). If an average pregnancy rate from embryo transfer of 60% is taken as a basis, an average of 2.3 pregnancies can be expected in practice from 3.8 embryos suitable for transfer, group I.
• the cattle in group I, control group with n 3, were treated in a different way from experiment 1 with a total dose of 16.9 mg NIH-FSH standard equivalent, folltropin, in the same way.
• the individual doses were 3.15 / 3.15 / 2.45 / 2.45 / 1.9 / 1.9 mg for the respective injection.
• the rabbit antiserum, 25 K antiseru, against inhibin was generated analogously to the MeLhode used in the rams
• the drug of the invention with the combination of antibodies and gonadotropins also leads to a considerable increase in this experiment the average number of eggs obtained and
• compositions of the 'invention is, however, applied as follows: take place multiple injections at defined time intervals, preferably in 12 or 24 hours over several days following aufein ⁇ other, preferably 3.5 to 4 days.
• the treatment is generally best in the luteal phase, preferably from the 7th to the 11th day of the cycle. In this interval, a new wave of growing follicles appears on the ovaries.
• a similar treatment regimen is used in embryo transfer when treating with gonadotropin.
• the medicament of the invention offers the technical advantage of an increased production of high quality, transferable embryos per flush of a donor animal with considerably more constant ovarian reactions.
• the medicament of the invention offers the further advantage that its use is also possible in those animal species which have not been stimulated up to now or have been able to be stimulated only with little success, in particular in mares.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Life Sciences & Earth Sciences (AREA)
• Endocrinology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6397731

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (2)

Citations (3)

Family Cites Families (3)

• 1990
  • 1990-01-08 DE DE4042408A patent/DE4042408C2/de not_active Expired - Fee Related
  • 1990-01-08 DE DE4000327A patent/DE4000327A1/de active Granted
• 1991
  • 1991-01-04 EP EP91902160A patent/EP0463138B1/de not_active Expired - Lifetime
  • 1991-01-04 DE DE59101599T patent/DE59101599D1/de not_active Expired - Fee Related
  • 1991-01-04 WO PCT/EP1991/000004 patent/WO1991010449A1/de not_active Ceased
  • 1991-01-04 AU AU70552/91A patent/AU649994B2/en not_active Ceased
  • 1991-01-04 CA CA002047723A patent/CA2047723A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events